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Abstract
Background—Emerging evidence implicates metabotropic glutamate receptor (mGluR) function
in the neurobiological effects of ethanol. The recent development of subtype specific mGluR
antagonists has made it possible to examine the roles of specific mGluRs in biochemical and
behavioral responses to ethanol. The purpose of the present study was to determine if mGluRs
modulate the acute sedative-hypnotic properties of ethanol in mice.
Methods—C57BL / 6J mice were tested for locomotor activity (sedation) and duration of loss of
the righting reflex (hypnosis) following acute systemic administration of ethanol alone or in
combination with the mGluR5-selective antagonist, 2-methyl-6-(phenylethynyl)pyridine (MPEP),
the mGluR1-selective antagonist, 7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxylate ethyl
ester (CPCCOEt), or the mGluR2 / 3-selective antagonist (2S)-2-Amino-2-[(1S,2S)-2-
carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid (LY341495)).
Results—MPEP (10 and 30 mg / kg) significantly enhanced both the sedative and hypnotic effects
of ethanol, while LY341495 (10 and 30 mg / kg) significantly reduced the sedative-hypnotic effects
of ethanol. CPCCOEt had no effect at any concentration tested. Further loss of righting reflex
experiments revealed that LY341495 (30 mg / kg) significantly reduced hypnosis induced by the
gamma-aminobutyric acid type A (GABAA) positive modulators, pentobarbital (50 mg / kg) and
midazolam (60 mg / kg), and the N-methyl-D-aspartate (NMDA) receptor antagonist, ketamine (150
mg / kg), while MPEP (30 mg / kg) only significantly enhanced the hypnotic properties of ketamine
(150 mg / kg).
Conclusions—These findings suggest that specific subtypes of the metabotropic glutamate
receptor differentially modulate the sedative-hypnotic properties of ethanol through separate
mechanisms of action, potentially involving GABAA and NMDA receptors.
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The amino acid glutamate is the primary excitatory neurotransmitter in the mammalian central
nervous system. Glutamate receptors are divided into 2 categories: iono-tropic receptors
(iGluRs), glutamate-gated cation channels including NMDA, α-amino-3-hydroxy-5-
methylisoxazole-4-propionic acid, and kainate responsive receptors, and metabotropic
receptors (mGluRs), a heterogeneous family of 7-transmembrane G-protein coupled receptors.
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Eight mGluR subtypes have been cloned. These receptors are divided into 3 broad groups based
on amino acid sequence similarity, agonist pharmacology, and second messenger coupling.
Group I mGlu receptors (mGluR1 and mGluR5) stimulate inositol phosphate metabolism and
mobilization of intracellular Ca2+, whereas group II (mGluR2 and mGluR3) and group III
(mGluR4, -R6, -R7, and -R8) inhibit adenylyl cyclase and reduce synaptic transmission
(Gereau and Conn, 1995; Kew and Kemp, 2005; Pin and Duvoisin, 1995). In contrast to the
iGluRs, which are responsible for the fast, excitatory responses to glutamate, mGluRs mediate
the slower, modulatory responses to glutamate. In this capacity, mGluRs can modulate
neurotransmission at both glutamatergic and nonglutamatergic synapses (Benquet et al.,
2002; Diaz-Cabiale et al., 2002).
The availability of selective pharmacological agents has begun to reveal basic functional roles
for the group I and II mGluR subtypes (Kew and Kemp, 2005). Group I selective agonists have
been shown to increase glutamate and GABA levels in vivo (de Novellis et al., 2003) and
enhance glutamate-evoked depolarization (Doherty et al., 1997; Pisani et al., 2001) and GABA-
gated Cl− currents (Hoffpauir and Gleason, 2002). Group II receptors are predominantly
presynaptic autoreceptors (Cartmell and Schoepp, 2000) and selective activation of these
receptors has been shown to reduce glutamate-evoked excitatory postsynaptic currents through
inhibition of glutamate release (Shen and Johnson, 2003). mGluR selective ligands have also
demonstrated behavioral activity in rodent models of anxiety and epilepsy. Group I antagonists
and group II agonists have been shown to have anxiolytic (Klodzinska et al., 1999; Spooren et
al., 2000) and anticonvulsant properties (Chapman et al., 2000; Moldrich et al., 2001).
Emerging evidence implicates mGluR function in ethanol’s neurobiological and behavioral
effects. Ethanol alters neuronal firing rates (Netzeband et al., 1997) and Ca2+ levels (Gruol et
al. 1997) mediated by mGluRs in vitro. Chronic exposure to ethanol reduces mGluR1 mRNA
levels in cerebellar Purkinje neurons of mice (Simonyi et al., 1996), and early withdrawal from
ethanol leads to alterations in mGluR-evoked Ca2+ signaling in cerebellar neurons (Netzeband
et al., 2002). In rats, chronic exposure to an ethanol containing liquid diet decreased mRNA
levels for mGluR3 and mGluR5 in the dentate gyrus, whereas mGluR1, mGluR5, and mGluR7
mRNA was decreased in the CA3 regions of the hippocampus (Simonyi et al., 2004).
Neurobehaviorally, mGluR5 selective antagonists reduce ethanol self-administration in mice
and rats (Cowen et al., 2005, 2007; Hodge et al., 2006; Lominac et al., 2006), decrease relapse
to ethanol self-administration in rats (Backstrom et al., 2004; Schroeder et al., 2005), and block
the discriminative stimulus effects of ethanol (Besheer and Hodge, 2005; Besheer et al.,
2006).
The purpose of this study was to investigate the role of specific mGluRs in the acute sedative
hypnotic effects of ethanol in mice. The 3 selective, systemically active mGluR antagonists 2-
methyl-6-(phenylethynyl)pyridine (MPEP; mGluR5), 7-(hydroxyimino)cyclopropa[b]
chromen-1a-carboxylate ethyl ester (CPCCOEt; mGluR1), and LY341495 (mGluR2/ 3) were
examined for their ability to alter ethanol-induced inhibition of spontaneous locomotor activity
(sedation) and ethanol-induced loss of righting reflex (LORR) (hypnosis). To explore potential
mechanisms by which mGluRs might modulate responses to ethanol, these antagonists were
also tested with other sedative-hypnotics: the GABAA positive modulators pentobarbital and
midazolam, and the NMDA antagonist ketamine. Blood-ethanol clearance studies were
conducted to ensure that the observed effects were not due to alterations in ethanol clearance.
MATERIAL AND METHODS
Animals
Male adult C57BL/ 6J mice (Jackson Labs, Bar Harbor, ME; 10 to 24 weeks; 22 to 35 g) were
housed 4 per cage and maintained on a 12-hour light/ dark cycle with food and water available
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ad libitum. Animal care and handling procedures were performed in accordance with approved
institutional protocols and the National Institutes of Health Guide for Care and Use of
Laboratory Animals (1996).
Drugs
Ethanol (95%w/ v) was diluted in physiological saline (0.9%) to a concentration of 20% (v/ v)
and administered in various volumes to obtain the appropriate doses. The mGluR1 selective
antagonist CPCCOEt, mGluR5 selective antagonist MPEP, and the group II selective (mGluR2
and mGluR3) antagonist LY 341495 were purchased from Tocris (Ellisville, MO, USA). The
mGluR5 selective antagonist 3-[(2-methyl-1,3-thiazol-4-yl)-ethynyl]-pyridine (MTEP) was
purchased from Ascent (Weston-super-Mare, UK). MPEP and MTEP were dissolved in
physiological saline (0.9%). CPCCOEt and LY 341495 were suspended in (2-Hydroxypropyl)-
β-cyclodextrin (45% w/ v, Sigma, St Louis, MO) in distilled water. Pentobarbital, midazolam,
and ketamine were purchased from Sigma-Aldritch and were dissolved in physiological saline
(0.9%). Drug and vehicle solutions were administered to mice in a volume of 0.1 ml/ 10 g body
weight, and dose selections were made based on pilot experiments and published studies
(Naveilhan et al., 2001; Quinlan et al., 1998).
LORR Studies
Animals were treated with vehicle, MPEP (10 to 30 mg/ kg), CPCCOEt (10 to 30 mg/ kg), or
LY341495 (10 to 30 mg/ kg) 10 minutes prior to ethanol treatment (4.0 g/ kg, IP) and the onset
and duration of LORR (sleep time) were measured. Onset was calculated as the time between
ethanol injection and LORR. LORR was defined as the inability of an animal to right itself
within 30 seconds. Upon LORR, mice were placed in V-shaped troughs (~90° angle) and the
time to regain righting reflex was measured. Return of the righting reflex was defined as the
ability of an animal to right itself 3 times in 30 seconds. Duration of LORR was calculated as
the difference between loss and return of righting reflex.
The active antagonists (MPEP and LY341495) were then further tested with a series of ethanol
doses (2.5 to 3.5 g/ kg) to examine ethanol dose-dependence. MTEP (10 mg/ kg) and MPEP
(10 mg/ kg) were also tested with ethanol (3 g/ kg) to further confirm mGluR5 involvement.
To examine possible mechanisms for the antagonist effects on ethanol-induced LORR,
pentobarbital (50 mg/ kg)-, midazolam (60 mg/ kg)-, and ketamine (200 mg/ kg)-induced
LORR were also examined following pretreatment with the active mGluR antagonists.
Locomotor Activity Studies
Spontaneous locomotor activity was measured in 8 ENV 250 activity chambers (Med.
Associates, St Albans, VT). Infrared light sources and photodetectors were used to measure
horizontal distance traveled during test sessions. All sessions were 60 minutes. Sessions were
recorded in 5-minute time bins at 100 ms resolution on a computer interfaced with the
chambers. Following each session, chambers were cleaned with glacial acetic acid and rinsed
with water.
All animals were chamber naive prior to testing. Vehicle, MPEP (30 mg/kg), CPCCOEt (30
mg / kg), or LY341495 (30 mg/ kg) was administered by intraperitoneal injection (IP) 10
minutes prior to ethanol treatment (0 and 2.0 g/ kg, IP). The animals were placed in the activity
chambers immediately after ethanol injection.
Blood Ethanol Clearance
Vehicle, MPEP (30 mg/ kg) or LY341495 (30 mg/ kg) was administered by IP injection 10
minutes prior to ethanol treatment (4.0 g/ kg). Blood (~30 μl) was taken from the tail vein at
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various time points (10, 30, 60, 120, 180 minutes) after ethanol administration. Plasma from
the samples was analyzed using an alcohol analyzer (Analox Instruments, Lunenburg, MA).
Analysis of Drug Effects
One-way ANOVA was used to determine the effects of the antagonists on single doses of
sedative-hypnotic compounds. Two-way ANOVA was used to analyze the effects of the
antagonists on total spontaneous locomotor activity and ethanol dose-dependent LORR. Three-
way ANOVA with repeated measures was used to analyze the time course of antagonist effects
on spontaneous locomotor activity. Two-way ANOVA with repeated measures and area under
the curve (AUC) calculations were used to evaluate the blood-ethanol data. Upon identification
of statistical significance, post hoc comparisons were made with a Tukey’s test where
appropriate. In all cases, a value of p < 0.05 was considered significant.
RESULTS
Ethanol-Induced LORR
Systemic administration of the selective mGluR5 antagonist MPEP (0 or 30 mg/kg) or the
mGluR2/ 3 antagonist LY 341495 (0 or 30 mg/ kg) produced differential effects on the time
required for animals to regain their righting reflex following a high dose of ethanol (Fig. 1).
Pretreatment with the highest dose of MPEP (30 mg/ kg) increased the duration of LORR
induced by ethanol (4 g/ kg) by 65% (Fig. 1A; F[2,25] = 13; p < 0.001). Follow-up analysis
shows that 30 mg/kg MPEP was significantly different from saline and 10 mg/kg MPEP
(Tukey; p < 0.05), indicating a dose-dependent effect of MPEP. In contrast, pretreatment with
the mGluR2/ 3 antagonist, LY341495, decreased the duration of ethanol-induced LORR (Fig.
1B). LY341495 significantly reduced the duration of LORR produced by ethanol (4 g/ kg) (F
[2,31] = 11; p < 0.001), although responses to the 10 and 30 mg/kg doses (54.2 ± 5.0 minutes
and 38.8 ± 5.3 minutes, respectively) were not significantly different from each other. Neither
dose of the mGluR1 antagonist CPCCOEt tested (10 and 30 mg/ kg) altered the duration of
ethanol-induced LORR (F[2,29] = 0.9; p = 0.415) (Fig. 1C).
Ethanol-Induced Locomotor Inhibition
mGluR5 and mGluR2/ 3 antagonists differentially modulated the ability of a subhypnotic dose
of ethanol (2.0 g/ kg) to reduce spontaneous locomotor activity as measured by distance
traveled in a novel environment. Two-way ANOVA revealed a main effect of ethanol on total
ambulatory distance (Fig. 2A; F[1,27] = 112; p < 0.001). When administered prior to ethanol,
MPEP (30 mg/ kg) further reduced exploratory locomotor activity compared with ethanol
control. Although the analysis shows no main effect of MPEP, there was a significant MPEP
× ethanol interaction (F[1, 27] = 22;p < 0.001), indicating that the effect of MPEP on total
motor activity depended on the dose of ethanol (Fig. 2A). Analysis of the time course of MPEP’s
effects on ethanol-induced sedation by 3-way RM ANOVA showed a significant interaction
among MPEP, ethanol, and time (Fig. 2B, F[11,297] = 2; p < 0.01) and a main effect of time
(F[11,297] = 43; p < 0.001), in addition to confirming the main effect of ethanol. Follow-up
analysis of these data showed that MPEP pretreatment significantly enhanced ethanol-induced
motor impairment during the first 5 minutes (Tukey; p < 0.001), as well as 25 and 55 minutes
post injection (Tukey; p < 0.05). Pretreatment with LY341495 (30 mg/ kg) reversed ethanol-
induced locomotor inhibition, producing a main effect of LY341495 (Fig. 2C; F[1,24] = 16;
p < 0.001) but no LY341495 × ethanol interaction. However, time course analysis by 3-way
RM ANOVA showed an interaction among LY341495, ethanol, and time (Fig. 2D; F[11,220]
= 2; p < 0.01) and a main effect of time (F[11,220] = 2; p < 0.001), while also confirming the
main effect of LY341495. LY341495 pretreatment significantly diminished ethanol-induced
motor impairment at 5, 10, 15, 20, 25, and 35 minutes after ethanol treatment (Tukey; p < 0.05).
Treatment with CPCCOEt (30 mg/ kg) had no effect on total locomotor activity when
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administered alone or prior to ethanol treatment (Fig. 2E; F[1,24] = 0.05; p = 0.83) and temporal
analysis showed no interaction among CPCCOEt, ethanol, and time (Fig. 2F).
Ethanol-Induced LORR: Ethanol Dose-Dependence
To further characterize the involvement of mGluR5 and mGluR2/ 3 receptors in ethanol-
induced hypnosis, the highest effective dose of each antagonist was tested in combination with
a range of ethanol doses. As shown in Fig. 3A, the duration of LORR was dose-dependently
increased by ethanol (F[3, 53] = 103; p < 0.001). At a dose of 2.5 g/ kg, ethanol did not induce
LORR. Doses of 3.0, 3.5, and 4.0 g/ kg of ethanol induced increasing durations of LORR. This
dose-dependent effect of ethanol was enhanced by MPEP pretreatment. Two-way ANOVA
showed a main effect of MPEP (30 mg/ kg) (F[1, 53] = 80; p < 0.001). After MPEP
pretreatment, the time to regain the righting reflex was significantly increased compared with
the corresponding saline pretreated controls at all doses of ethanol tested (Tukey; p-values ≤
0.002). MPEP pretreatment also altered the sedative-hypnotic effects of the lowest dose of
ethanol, resulting in a LORR when combined with 2.5 g/kg ethanol. However, there was no
MPEP × ethanol interaction.
Figure 3B shows the ethanol dose–response curve following vehicle and LY341495
pretreatment. Two-way ANOVA showed that both ethanol and LY341495 produced main
effects (EtOH: F[2, 41] = 27; p < 0.001); LY341495: (F[1, 41] = 12; p = 0.001). Analysis also
showed a significant LY341495 × ethanol interaction (F[2, 41] = 5; p = 0.015), indicating that
LY341495 effects are dependent on ethanol dose. LY341495 (30 mg/ kg) significantly
reducfed the duration of ethanol-induced LORR for a 4.0 g/ kg ethanol dose (Tukey; p < 0.001),
but not for the 3.0 or 3.5 g/ kg doses.
Examination of the time to onset of LORR also demonstrated differences in the actions of
MPEP and LY341495. As shown in Table 1, MPEP pretreatment resulted in a more rapid onset
of LORR for the 3.0 and 3.5 g/kg doses of ethanol (F[2, 39] = 20; p = 0.001), while LY341495
pretreatment had no effect on onset time.
Ethanol-Induced LORR: mGluR5 Specificity
To further confirm the mGluR5 involvement, a low dose of MPEP and the highly potent and
selective mGluR5 antagonist MTEP were tested in parallel with a lower hypnotic dose of
ethanol (3 g/ kg). As shown in Fig. 4, both MPEP (10 mg/ kg) and MTEP (10 mg/kg)
significantly increased the duration of LORR induced by ethanol (3 g/ kg). The duration of
ethanol-induced LORR was increased by 86% by MPEP and 133% by MTEP (F[2,21] = 13;
p < 0.001). There was not a significant difference between the effects of MPEP and MTEP on
ethanol-induced LORR suggesting that the effects observed following MPEP (30 mg/ kg) are
attributable to its actions on mGluR5.
Pentobarbital and Midazolam-Induced LORR
The GABAAR positive modulator pentobarbital (50 mg/ kg) induced an average duration of
LORR comparable to that produced by a 4 g/ kg dose of ethanol. Pretreatment with MPEP (30
mg/ kg) did not alter the onset time or duration of LORR in mice treated with pentobarbital
(Table 2). In contrast, LY341495 (30 mg/ kg) significantly increased onset time (F[1,13] = 14;
p = 0.002) and shortened the duration of pentobarbital-induced LORR by 67% (F[1,13] = 39;
p < 0.001). The GABAAR benzodiazepine positive modulator midazolam (60 mg/ kg) also
produced an average duration of LORR similar to the highest dose of ethanol. Midazolam-
induced LORR was unaffected by MPEP and completely reversed by LY 341495 (Table 2;
Onset: F[1,6] = 12; p = 0.013; duration: F[1,6] = 23; p = 0.003).
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Like ethanol, the NMDA receptor antagonist ketamine (200 mg/ kg)-induced hypnosis was
differentially affected by pretreatment with MPEP and LY341495 (Table 2). MPEP (30 mg/
kg) increased the duration of LORR in mice treated with ketamine by 39% (F[1,13] = 85; p <
0.001), while LY341495 (30 mg/ kg) reduced ketamine-induced LORR by 20% (F[1,13] = 12;
p = 0.004). Onset time was unaffected by either MPEP or LY341495 treatment.
Blood Ethanol Determination
To address the possibility that MPEP and LY341495 are eliciting their effects by altering
ethanol metabolism, blood-ethanol concentrations were measured following a 4 g/kg dose of
ethanol (Table 3). In vehicle treated animals, blood-ethanol concentrations decreased
significantly over time (saline: F[4,79] = 79; p < 0.001; cyclodextrin: F[4,88] = 42; p < 0.001).
Neither MPEP (30 mg/ kg; F[1,22] = 0.987; p = 0.331) nor LY341495 (30 mg/ kg; F[1,14] =
1.3; p = 0.274) pretreatment altered the blood-ethanol clearance time course. However,
comparisons of the blood ethanol concentrations of saline and cyclodextrin treated animals
revealed significant differences between the 2 vehicle groups (F[1,100] = 10; p = 0.003; AUC:
F[1,22] = 11; p = 0.003), specifically at the 120 and 180 minute time points (p < 0.05).
DISCUSSION
The purpose of this study was to investigate the role of specific mGluRs in the acute sedative-
hypnotic effects of ethanol in mice by examining the effects of mGluR selective antagonists
on ethanol-induced sedation and hypnosis. One of the primary findings of the present study is
the mGluR5 antagonist MPEP increased ethanol-induced locomotor inhibition and LORR.
These findings indicate that the inhibition of mGluR5 activity enhances the acute sedative-
hypnotic effects of ethanol. Moreover, the more selective mGluR5 antagonist MTEP produced
a comparable effect on ethanol-induced LORR, further supporting the conclusion that mGluR5
activity influences the sedative-hypnotic properties of ethanol. Although the exact role of
mGluR5 in ethanol’s pharmacological effects has not been identified, these results suggest that
ethanol produces some of its acute inhibitory effects through negative modulation of mGluR5
activity. This hypothesis is supported by evidence showing that pharmacologically relevant
concentrations of ethanol inhibit glutamate-induced Ca2+-dependent Cl− currents in Xenopus
oocytes expressing mGluR5 (Minami et al., 1998). Furthermore, this inhibition of mGluR5 is
PKC dependent. Because acute ethanol activates PKCγ in vivo (Wilkie et al., 2007), which
desensitizes mGluR5 through phosphorylation (Gereau and Heinemann, 1998), it is possible
that ethanol inhibits mGluR5 activity through PKC-dependent desensitization.
The other group I antagonist tested, the mGluR1 selective CPCCOEt, had no effect on ethanol-
induced sedation or hypnosis. The absence of an effect for CPCCOEt is consistent with
evidence suggesting that group I mGluR mediation of ethanol effects is specific to mGluR5.
Acute ethanol treatment does not affect Cl− currents in mGluR1-expressing oocytes (Minami
et al., 1998), and our laboratory has shown no effect of CPCCOEt on ethanol consumption in
either C57BL/ 6J mice or alcohol-preferring (P) rats (Hodge et al., 2006; Schroeder et al.,
2005). However, our current results are inconsistent with a similar study (Lominac et al.,
2006), which shows that pretreatment with CPCCOEt, but not MPEP, facilitates ethanol-
induced motor impairment. While it is not entirely clear why these discrepancies exist, it may
be due to differences in experimental procedure. We chose to use a higher dose of MPEP (30
mg/ kg) based on our initial LORR study that showed no effect of a 10 mg/kg when paired
with a 4 g/ kg dose of ethanol. Furthermore, we employ a shorter pretreatment time. The onset
to LORR and temporal distribution analysis of locomotor behavior both suggest that MPEP’s
behavioral effects are rapidly induced, implying that a shorter pretreatment time is necessary
to see MPEP effects. Furthermore, our data showing that both a lower dose of MPEP and
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another mGluR5 selective antagonist, MTEP, increase the duration of LORR produced by a
lower dose of ethanol (3 g/ kg) support the conclusion that selective blockade of mGluR5
enhances ethanol’s sedative-hypnotic effects. As for the differences in CPCCOEt effects, the
longer pretreatment time and longer testing time used by Lominac et al. (2006) may be
necessary for the expression of CPCCOEt enhancement of ethanol-induced motor impairment.
This study also shows that the mGluR2/ 3 antagonist, LY341495, decreased both the sedative
and hypnotic effect of ethanol. Both doses of LY341495 (10 and 30 mg/ kg) reduced ethanol-
induced LORR. LY341495 (30 mg/ kg) also reversed the sedative effects of ethanol, as
measured by spontaneous locomotor activity. These results were not unexpected given that
LY341495 has been shown to have locomotor activating properties (David and Abraini,
2001). A growing body of evidence indicates that group II mGluRs are presynaptic
autoreceptors and blockade of these receptors with LY341495 increases glutamate release (Xi
et al. 2002). Increases in presynaptic glutamate release are known to promote increased
locomotor activity (Vezina and Kim, 1999), suggesting that reductions in ethanol-induced
sedation and hypnosis by LY341495 are due to increased glutamatergic activity.
The ethanol dose–response data highlight other differences between the mGluR5 and mGluR2/
3 effects. The mGluR5 antagonist MPEP produced a significant increase in the duration of
LORR regardless of the dose of ethanol administered. Furthermore, the increases produced by
MPEP were the same for each dose of ethanol. Although MPEP alone produced no sedative-
hypnotic effects, combination with a sub-hypnotic dose of ethanol (2.5 g/ kg) produced full
hypnosis and a duration of LORR similar to the increases seen when MPEP was combined
with fully hypnotic doses of ethanol. In contrast, the mGluR2/ 3 antagonist LY341495
produced a significant decrease in the duration of LORR only when administered with the
highest dose of ethanol. These results indicate that the effects of LY341495 are dependent on
the dose of ethanol administered. The onset to LORR data also present a distinction between
the actions of MPEP and LY341495. Pretreatment with MPEP resulted in a more rapid onset
of LORR for the 2 lower doses of ethanol (3.0 and 3.5 g/ kg), providing further evidence that
MPEP enhances the hypnotic properties of ethanol and does so rapidly. Pretreatment with
LY341495 did not alter the onset of LORR at any of the ethanol doses tested.
Ethanol-induced hypnosis has been attributed largely to ethanol’s ability to enhance inhibitory
GABAergic responses and impair excitatory NMDA receptor activity (Beleslin et al., 1997).
For an understanding of the mechanisms by which MPEP and LY341495 alter ethanol-induced
hypnosis and a clarification as to whether these compounds selectively alter ethanol effects,
MPEP and LY341495 were also tested ith the GABAA receptor positive modulators,
pentobarbital and midazolam, and an NMDA receptor antagonist, ketamine, that exhibit
hypnotic properties. MPEP pretreatment increased the duration of LORR for ketamine but had
no effect on the hypnotic properties of pentobarbital or midazolam. This finding is consistent
with reports that MPEP reduces NMDA-evoked responses (Attucci et al., 2001) and
antagonism of mGluR5 and NMDA receptors have additive detrimental effects on learning
and memory (Homayoun et al., 2004). Our results for pentobarbital and midazolam appear to
be at odds with reports that mGluR5 activation positively modulates GABAA receptor function
in vitro (Hoffpauir and Gleason, 2002), although this may be specific to benzodiazepine-
sensitive GABAA receptors as MPEP inhibits the ethanol-like stimulus properties of diazepam,
but not pentobarbital (Besheer and Hodge, 2005). However, it has also been reported that the
anxiolytic effects of MPEP do not involve benzodiazepine-sensitive GABAA receptors
(Wieronska et al., 2004), indicating that further research must be done to determine the extent
to which mGluR5 interacts with GABAA receptors in vivo. Overall, these results suggest that
blockade of mGluR5 increases the hypnotic properties of ethanol by enhancing ethanol-
induced inhibition of NMDA receptors without affecting ethanol’s actions at GABAA
receptors.
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LY341495 reduced the duration of LORR for ketamine and pentobarbital and fully blocked
induction of midazolam-induced LORR. These data are consistent with evidence showing that
LY341495 has general stimulant effects (David and Abraini, 2001). While LY341495 reversed
the hypnotic effects of all 3 drugs, it did so to varying degrees. LY341495 reduced ketamine-
induced LORR by 20%, pentobarbital-induced LORR by 67%, and midazolam-induced LORR
by 100%. Interestingly, LY341495 appears to be least effective at reversing hypnosis induced
by NMDA receptor inhibition. Based on our hypothesis that LY341495 reverses hypnosis by
increasing glutamate release, these data suggest that the inhibition of mGluR2/3 results in
enough glutamate release to counteract enhanced GABAAR activity, but not enough to prevent
decreased glutamatergic activity due to NMDAR inhibition.
One limitation of the present study that merits discussion is the potential off target effects of
the pharmacological compounds tested. High concentrations of MPEP (20 μM and above) have
been associated with NMDA receptor inhibition (O’Leary et al., 2000) and positive allosteric
modulation of mGlu4 receptors (Mathiesen et al., 2003). However, it has been reported that
systemic administration of a 3 mg/ kg dose of MPEP produces submicromolar concentrations
in the brain (0.83 μM; (Cosford et al., 2003), making it unlikely that a 30 mg/kg dose of MPEP
would result in brain concentrations high enough to significantly affect NMDA or mGlu4
receptors. It has also been reported that MPEP can inhibit the norepinephrine transporter at
nanomolar concentrations (Heidbreder et al., 2003), which may be related to the effects we
report, given that the norepinephrine transporter has been implicated in the differential ethanol
sensitivities of the long-sleep and short-sleep mice (Haughey et al., 2005). However, given that
a low dose of MPEP (10 mg/ kg) and the more selective mGluR5 antagonist MTEP (Varty et
al., 2005) both enhanced the hypnotic effects of a low dose of ethanol, off target effects of
MPEP do not appear to be a concern here.
Although there is currently no evidence that LY341495 has any off target effects, another
mGluR2/ 3 antagonist has been shown to increase extracellular dopamine levels (Karasawa et
al., 2006). Thus, additional research using gene knockout mice, RNA inhibition, or other more
selective approaches are warranted to examine the selectivity of these compounds. The dose
of ketamine used to induce LORR may also be having off target effects, namely at
dopaminergic or nicotinic acetylcholine systems. As ketamine has been shown to increase
extracellular dopamine release (Aalto et al., 2005), it is unlikely that interactions with
dopaminergic systems are contributing to ketamine’s sedative-hypnotic profile. Ketamine has
also been shown to inhibit α7-containing nicotinic acetylcholine receptors (nAChR) (Coates
and Flood, 2001). This interaction may play a role in ketamine-induced hypnosis, as α7-subunit
null mutant mice are more sensitive to the sedative-hypnotic properties of ethanol (Bowers et
al., 2005), and in the MPEP and LY341495 modulation of induced sedation, as recent evidence
suggests a link between mGluR function and α7-nAChR (Welsby et al., 2006). Again, further
research is necessary to determine the roles of each of these systems.
Finally, neither MPEP nor LY341495 altered blood-ethanol clearance. However, cyclodextrin,
the vehicle used for LY341495 and CPCCOEt, appears to slow the time course of ethanol
elimination as compared with saline. While these differences do not invalidate results from
individual experiments, it limits the comparisons that can be made between saline vehicle and
cyclodextrin vehicle experiments. These differences may contribute to the variability seen for
the 3 vehicle groups in the locomotor activity experiments.
In summary, the present data suggest that specific subtypes of metabotropic glutamate
receptors differentially modulate ethanol-induced sedation and hypnosis without altering the
pharmacokinetics of ethanol elimination. Inhibition of mGluR5 enhances the sedative-
hypnotic effects of ethanol, whereas inhibition of mGluR2/ 3 reverses these effects of ethanol.
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Our results also suggest that mGluR5 and mGluR2/ 3 elicit these changes through differential
modulation of GABAA and NMDA receptors.
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Effects of mGluR antagonists on loss of righting reflex (LORR). Bars represent the mean
(±SEM) duration of ethanol-induced LORR in minutes (n = 6 to 8) following pretreatment
with MPEP (A), CPCCOEt (B), or LY341495 (C). *Significantly different from 4 g / kg ethanol
alone (p < 0.05, Tukey’s test).
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Effects of mGluR antagonists on total locomotor activity alone and in the presence of a sedative
dose of ethanol (A, C, and E). Bars represent the mean (±SEM) horizontal distance traveled
in 60 minutes (n = 6 to 8) following pretreatment with vehicle, MPEP (30 mg / kg) (A),
LY341495 (30 mg / kg) (C), or CPCCOEt (30 mg / kg) (E) with and without ethanol (2.0 g /
kg). *Significantly different from vehicle / vehicle (p < 0.05, Tukey’s test). **Significantly
different from vehicle / ethanol (p < 0.05, Tukey’s test). Temporal analysis of mean (±SEM)
horizontal distance traveled in 5 minute time intervals (n = 6 to 8) following treatment with
vehicle, MPEP (30 mg / kg) (B), LY341495 (30 mg / kg) (D), or CPCCOEt (30 mg / kg) (F)
with and without ethanol (2.0 g / kg). *mGluR antagonist / ethanol treatment significantly
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different from vehicle / ethanol treatment at given time point (p < 0.05, Tukey’s test). *mGluR
antagonist / vehicle treatment significantly different from vehicle / vehicle at given time point
(p < 0.05, Tukey’s test).
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Ethanol-induced loss of righting reflex (LORR) plotted as a function of ethanol dosage,
symbols represent the mean (±SEM) duration of LORR in minutes (n = 8) following ethanol
with saline pretreatment (open symbols) or in combination with MPEP (A) or LY341495 (B)
pretreatment (closed symbols). *Significantly different from vehicle at corresponding dose of
ethanol (p < 0.05, Tukey’s test).
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Confirmation of mGluR5 specificity in loss of righting reflex (LOSS). Bars represent mean
(±SEM) duration of ethanol-induced LORR in minutes (n = 8) following pretreatment with
saline, MPEP, or MTEP. *Significantly different from saline pretreatment (p < 0.05, Tukey’s
test).
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Table 1
Effects of mGluR Antagonists on Onset to Ethanol-Induced Loss of Righting Reflex
MPEP dose(mg / kg) LY341495 dose(mg/ kg)
Ethanol (g / kg) 0 30 0 30
3.0 2.4 ± 0.1 1.9 ± 0.1* 3.1 ± 0.2 3.2 ± 0.2
3.5 1.8 ± 0.2 1.2 ± 0.2* 2.6 ± 0.2 2.5 ± 0.2
4.0 1.5 ± 0.1 1.2 ± 0.1 1.9 ± 0.1 2.0 ± 0.2
Data expressed as mean ± SEM minutes (n = 8 to 10).
*
Significantly different from ethanol alone (p < 0.001, Tukey’s test).
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